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Aims: NADPH oxidase (NOX) is a known source of superoxide anions in phagocytic and non-phagocytic cells.
In this study, the presence of this enzyme in human pancreatic islets and the importance of NADPH oxidase in
human β-cell function were investigated.
Main methods and key ﬁndings: In isolated human pancreatic islets, the expression of NADPH oxidase compo-
nents was evidenced by real-time PCR (p22PHOX, p47PHOX and p67PHOX), Western blotting (p47PHOX and
p67PHOX) and immunohistochemistry (p47PHOX, p67PHOX and gp91PHOX). Immunohistochemistry experiments
showed co-localization of p47PHOX, p67PHOX and gp91PHOX (isoform 2 of NADPH oxidase—NOX2) with insulin
secreting cells. Inhibition of NADPH oxidase activity impaired glucose metabolism and glucose-stimulated insu-
lin secretion.
Signiﬁcance: These ﬁndings demonstrate the presence of the main intrinsic components of NADPH oxidase com-
prising the NOX2 isoform in human pancreatic islets, whose activity also contributes to human β-cell function.© 2012 Elsevier Inc. Open access under the Elsevier OA license.Introduction
The classical NADPH oxidase (NOX) is a heteromultimeric enzyme
which was ﬁrst described in phagocytes (Bedard and Krause, 2007)
composed of the membrane-bound cytochrome b558 (gp91PHOX also
referred to as NOX2, and p22PHOX), three cytosolic components
(p40PHOX, p47PHOX and p67PHOX) and a low-molecular-weight Rho
GTPase (Rac1 or Rac2) (Babior, 2004). The transmembrane NOX2
protein, which is the catalytic core of this enzyme, generates superox-
ide upon its activation by interaction with the cytosolic p47PHOX,
p67PHOX, p40PHOX subunits, and one of the small Rho GTP-binding
proteins (Sorce and Krause, 2009). Recruitment of the cytosolic
components to the membrane occurs through protein kinase C (PKC)-
mediated p47PHOX serine phosphorylation, in which the serine residues
S303, S304, S358 and S370 play a key role for recruitment (Babior,
2004). The interaction of these cytosolic components with cytochrome
b558 is mediated by its p22PHOX subunit. NOX2 is then activated by
p67PHOX, assembling the oxidase activity (Sorce and Krause, 2009).
The presence of the NADPH oxidase isoform whose activity is
dependent on p47PHOX translocation, i.e. NOX2, and of other NOX
isoforms (NOX1 and NOX4) has been reported in rat pancreatic isletsy and Biophysics, Institute of
rofessor Lineu Prestes, 1524,
5 11 3091 7285.
vier OA license.(Oliveira et al., 2003; Uchizono et al., 2006). In β-cells NOX2 appeared
to be involved in oxidative stress induced by high chronic glucose levels
in glucotoxicity (Yuan et al., 2010). Interestingly, although NOX2
deﬁciency protected against streptozotocin-induced β-cell destruction
(Xiang et al., 2010), the suppression of its activity also impaired the
mechanisms of glucose-stimulated insulin secretion (GSIS) in rodent
islets (Imoto et al., 2008; Morgan et al., 2009). These observations sug-
gest the involvement of NADPH oxidase in the function and dysfunction
of pancreatic islets cells, whichmay depend on the stimulus presented.
Despite the fact that reports on the involvement of NADPH oxi-
dase in the function and dysfunction of rodent pancreatic islets are
increasing, there is limited information regarding human islets. A
possible implication of NADPH oxidase in human β-cell dysfunction
was raised by the report of high p22PHOX mRNA levels in pancreatic
islets from type 2 diabetic patients (Marchetti et al., 2004). Protein
expression (gp91PHOX and p47PHOX) has been recently demonstrat-
ed, whereas no changes were observed between normal and diabetic
human islets (Syed et al., 2011). However, there is no investigation
concerning the presence of the functional NADPH oxidase complex
and the possible implications of this enzyme in human β-cell
physiology.
In this study, we investigated the presence and participation of
NADPH oxidase in human islet function. The components of the
NOX2 isoform are expressed in human pancreatic islets and the inhi-
bition of the enzyme activity suppressed glucose metabolism and
GSIS. Thus, the presence and activity of this enzyme appears to be sig-
niﬁcant for human pancreatic β-cell functioning.
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Isolation and culture of human pancreatic islets
Human pancreas from adult brain-dead donors (mean age 45±
3 years, n=19) were harvested in accordance with Brazilian regula-
tions and the local institutional ethics committee. Pancreatic islets
were isolated after ductal distension of the pancreas and digestion
of the tissue with Liberase H1 (Roche Diagnostics, Indianapolis, IN)
or collagenase NB1 premium grade and neutral protease NB (Serva
Electrophoresis GmbH, Heidelberg, Germany), according to the auto-
mated method of Ricordi et al. (1988) with modiﬁcations (Shapiro et
al., 2000). Islet puriﬁcation was achieved using a continuous Ficoll
density gradient in a COBE 2991 cell processor (Gambro, Lakewood,
CO). The islet preparations used in this study exhibited 70±4% purity
as determined by dithizone staining. Islet cell viability, which was
usually greater than 80%, was evaluated using the live/dead ratio ﬂuo-
rescent method, based on the incorporation of either acridine orange
(Sigma, St. Louis, MO) by live cells or propidium iodide (Sigma) by
dead cells. After isolation and puriﬁcation, human islets were cultured
in CMRL-1066 medium (Mediatech, Inc., Manassas, VA) supplemented
with 5.6 mM glucose, 0.5% human serum albumin (HSA), 10 mM nico-
tinamide, 6 μM vitamin E and antibiotics for at least 24 h at 37 °C and
5% CO2.
Real-time polymerase chain reaction (real-time PCR)
Total RNA from 48 h-cultured human pancreatic islets and from
fresh human peripheral bloodmononuclear cells (PBMC) was prepared
as previously described (Sogayar et al., 2004)withminormodiﬁcations.
RNA integrity was electrophoretically veriﬁed by both ethydium bro-
mide staining and 260/280 nm absorption ratio >1.95. cDNA was gen-
erated from the RNA samples using SuperScript (Invitrogen, Carlsbad,
CA). The primers used for gene ampliﬁcation by real-time PCR were
designed using the Primer Express 3.0 software (Applied Biosystems,
Foster City, CA) and fed into a 7300 real-time PCR system thermocycler
(Applied Biosystems, Foster City, CA). PCR reactions were quantiﬁed
using the SYBR® Green dye reagent (Applied Biosystems, Foster City,
CA). For each primer, the real-time PCR efﬁciency (E) of one cycle in
the exponential phase was calculated according to the equation: E=
10[−1/slope] (Rasmussen et al., 2001). In order to guarantee an mRNA
expression level that ensures speciﬁc ampliﬁcation, the PCR reactions
were only used for analysis when the CT was less or equal to 30. The
following primers were used in this study: human gp91PHOX (F: 5′
GTCGCCTATGGGATAGCTGTTAA 3′; R: 5′GGTAGCGTTCCAGGTTGAAG
AA3′), human p22PHOX (F: 5′TCCGGCCTG ATCCTCATC 3′; R: 5′AATGGA
GTAGGCACCAAAGTACCA3′), human p47PHOX (F: 5′GCTGGTGGGTCATC
AGGAAA3′; R: 5′GCCCTGACTTTTGCAGGTACA3′), human p67PHOX (F:5′
CCTG CAACTACCTTGAACCAGTT3′; R:5′GGACTGCGG AGAGCTTTCC3′),
and hypoxanthine phosphoribosyl transferase (HPRT) (F: 5′GAACGTC
TTGCTCGAGATGTGA3′; R: 5′TCCAGCAGGTCAGCAAAGAAT3′).
Management of the thermocycler and assessment of the results
generated during ampliﬁcation were performed using the SDS soft-
ware version 1.3.1 (Applied Biosystems, Foster City, CA). All real-
time PCR reactions were performed in triplicate for each independent
experiment. The relative expression of target genes was determined
in comparison to a reference gene (Livak and Schmittgen, 2001),
which was chosen to be a stable and unregulated transcript, the
HPRT housekeeping gene transcript.
Western blotting
Eighty micrograms of proteins from 48 h-cultured human islet ex-
tracts and forty micrograms of proteins from fresh human neutrophil
extracts were solubilized in a sample buffer (60 mM Tris–HCl [pH:
6.8]), 2% sodiumdodecyl sulfate (SDS, 10% glycerol, 0.01% bromophenolblue) and subjected to SDS-polyacrylamide gel (7.5%) electrophoresis
(PAGE). Proteins were transferred to nitrocellulose membranes, which
were blocked and then incubated with polyclonal anti-human anti-
bodies: p47PHOX (07‐001; Upstate Biotechnologies, Temecula, CA) and
p67PHOX (sc-15342; Santa Cruz Biotechnology Inc., Santa Cruz, CA).
The membranes were then incubated with horseradish peroxidase-
conjugated secondary antibody (Vector Laboratories, Burlingame, CA).
The proteins were visualized by an enhanced chemiluminescence assay
performed according to the manufacturer's instructions (Amersham
Biosciences, Buckinghamshire, UK).
Immunohistochemistry
Human pancreatic islets were ﬁxed in 1% paraformaldehyde
dissolved in 100 mM phosphate buffer (PB), pH 7.3, for 30 min and
cryoprotected in 10% sucrose solution at 4 °C. The islets were frozen
in tissue freezing medium (TBS, Durham, NC) and cut (12 μm) in a
cryostat. The sections were kept at 37 °C for 30 min in gelatinized
slides and stored at−20 °C until use. For the immunohistochemistry
assays, the islet sections were blocked for 2 h in a solution containing
5% normal goat serum and 0.3% Triton X-100 in PB. In order to deter-
mine the expression of p47PHOX, p67PHOX and gp91PHOX, antibodies
against the respective proteins were used (Upstate Biotechnology,
Temecula, CA) in a 1:50 dilution with 0.3% Triton X-100 in PB. Guinea
pig insulin antibody (1:200) was used for the double-labeling exper-
iments. The islet sections were incubated with the primary antibodies
overnight at room temperature. After several washes, sections were
incubated for double- and single-labeling experiments with second-
ary antibodies conjugated to ﬂuorescein isothiocyanate (FITC; Jackson
Labs, West Grove, PA; 1:100), and to tetramethyl rhodamine isothio-
cyanate (TRITC; Jackson Labs; 1:100) in 0.3% Triton X-100 in PB. After
washing, the tissue was mounted using Vecta Shield (Vector Labs,
Burlingame, CA). Protein expression and co-localization were ana-
lyzed in 0.5 μm optical sections on a confocal microscope (LSM 510,
Axiovert 100 M, Carl Zeiss, Jena, Germany). Controls for the experi-
ments consisted of the omission of primary antibodies, with no
staining being observed.
Measurement of superoxide production by human islets
Batches of 20 human islets were incubated for 30 min at 37 °C in
500 μL Krebs–Henseleit medium containing 16.7 mM glucose in the
absence and in the presence of diphenyleneiodonium (DPI−10 μM)
or polyethylene glycol-conjugated superoxide dismutase (PEG-SOD
100 U/mL). For the experiments using PEG-SOD the islets were
pre-incubated for 1 h at 5.6 mM glucose in the absence or presence
of 100 U/mLPEG-SOD followedby incubation for 30 min in 16.7 mMglu-
cose also in the absence and in the presence of PEG-SOD (100 U/mL).
Hydroethidine (HEt) at a ﬁnal concentration of 100 μM was added and
the islets were incubated for an additional 20 min protected from light
at room temperature. After this period, the islets were washed twice
with Krebs–Henseleit buffer without glucose and analyzed by confocal
microscopy using an excitation wavelength set at 488 nm and an emis-
sion wavelength between 560 and 615 nm (LSM 510, Axiovert 100 M,
Carl Zeiss). HEt oxidation was quantiﬁed by the ﬂuorescence emission
intensity corrected for the islet area as previously published (Morgan
et al., 2007). The images were acquired using a 40× objective and the
same parameters were used for the analysis of all samples in each
experiment.
Measurement of [U–14C]-glucose oxidation
Groups of 100human isletswere incubated in 2.4 mLKrebs–Henseleit
buffer containing albumin (0.2%), at 37 °C, for 1 h in glass vials
containing a ﬁlter paper and 400 μL phenylethylamine, diluted to
1:1 v/v inmethanol, in a separated compartment. The incubation buffer
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[U–14C]-glucose for 16.7 mM glucose in the absence and in the presence
of 10 μM DPI or of 300 μM apocynin. Incubation was stopped by adding
400 μL HCl (10 M) and the vials were shaken for an additional 90 min.
The ﬁlter paper with phenylethylamine was transferred to a plastic
tube containing 1.8 mL biodegradable scintillation liquid and the 14CO2
adsorbedwas measured in a scintillation counter (Beckman Instruments,
Fulerton, CA, USA).
Measurement of glucose-stimulated insulin secretion in the presence of
NADPH oxidase inhibitors
Cultured human islets were washed with PBS, resuspended in RPMI
1640 medium without glucose and pre-incubated for 30 min at 37 °C.
Triplicate batches of 100 islet equivalents (IEQs) were incubated at
37 °C for 2 h in 1.5 mL RPMI 1640 medium supplemented with 0.5%
human serum albumin in the presence of 2.8 mM or 16.7 mM and
20 mM glucose in the absence or presence of one of the following
NADPH oxidase inhibitors: 10 μM DPI, and 60 or 300 μM apocynin.
This conditioned medium was collected from each well and insulin
was measured by electrochemiluminescence assay ELECSYS (Sapin
et al., 2001) (Roche Diagnostics, Indianapolis, IN). The limit of detection
of this assay is 0.2 μU/mL (1.39 pM). The results were normalized on
the basis of the DNA content and presented as the relative value to
that in 2.8 mM glucose from ﬁve independent experiments (triplicate
measurements for each experiment).
Statistical analysis
For the measurements of superoxide content and static insulin
secretion a glucose condition was set as the control for the adjustmentFig. 1. Gene expression of NADPH oxidase components. A) The mRNA levels of NADPH
oxidase subunits were analyzed by real‐time PCR using 1 μg of RNA from human
peripheral bloodmononuclear cells (PBMC) and humanpancreatic islets. B)Measurement
ofmRNA levels of p22PHOX; p67PHOX and p47PHOX at different periods of time in culture (24
and 48 h), relative to the 0 h culture (n=7). *Pb0.05 vs 0 h.
Fig. 2. Protein levels of the NADPH oxidase components. Primary cultures of human
pancreatic islets (48 h) were lysed. The protein levels of p47PHOX (A) and p67PHOX
(B) were measured by Western blotting. Eighty micrograms of proteins from human
pancreatic islets (PI) and forty micrograms of proteins from human neutrophils (NE)
were loaded into the gel. Tubulin was used as loading control. The immunoblots are
representative of ﬁve independent experiments. The densitometry graphs shown are
corrected for the different amounts of protein loaded between samples. *Pb0.05 and
***Pb0.001 vs NE.of each independent experiment. The results are presented as
means±SEM. Statistical analysis was performed with Student's t test
or one-way ANOVA followed by Tukey's multiple comparison post-
test as appropriate. Differences were considered to be signiﬁcant for
Pb0.05.
Results
The gene expression of the NADPH oxidase membrane-bound
component p22PHOX and of the cytosolic components p47PHOX and
p67PHOX in human pancreatic islets was examined by real time PCR,
using human peripheral blood mononuclear cells (PBMC) as positive
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similar in pancreatic islets (Fig. 1A). The mRNA levels of p22PHOX and
p67PHOX in pancreatic islets remained stable during the culture period
(Fig. 1B). However, the mRNA levels of p47PHOX were increased after
24 h in culture (Fig. 1B). Therefore, the experiments were performed
in human islets cultured for at least 24 h, when the mRNA of p47PHOX
attained stable levels. The protein expression of the cytosolic compo-
nents p47PHOX and p67PHOX of NADPH oxidase was evaluated by
Western blotting (Fig. 2A and B). Although the protein amount used
for human islet labeling was twice that for human neutrophils (posi-
tive control), the content of p47PHOX and p67PHOX protein was much
lower in human islets than in human neutrophils. In three of ﬁve
human pancreatic extracts, p67PHOX was identiﬁed as a double band
instead of the single one detected in the extract of human neutrophils
(Fig. 2B), as previously observed in rat islets (Oliveira et al., 2003).
Immunohistochemistry analysis conﬁrmed the presence of p47PHOX,
p67PHOX and gp91PHOX proteins in human pancreatic islets, with no
ﬂuorescence being observed in the negative control (Fig. 3A). TheFig. 3. Immunoﬂuorescence of NADPH oxidase components. A) Fluorescence detection (gree
panel) and corresponding phase contrast images of the islets (lower panel). B) Co‐localiza
with insulin staining (red). The images are representative of six independent experiments.green-labeling in the upper panel of Fig. 3B also refers to the
p47PHOX, p67PHOX and gp91PHOX protein expressions in human pan-
creatic islets, which are overlaid with insulin labeling shown in red
(middle panel). The co-localization of NADPH oxidase components
within insulin secreting cells from human pancreatic islets is demon-
strated by the yellow color in the lower panel (Fig. 3B).
The NADPH oxidase activity was evaluated by superoxide produc-
tion, that was decreased by DPI (10 μM), a pharmacological inhibitor
of NADPH oxidase (Fig. 4). Hydroethydine (HEt) oxidation by super-
oxide was evaluated by the addition of membrane-permeable super-
oxide dismutase (PEG-SOD 100 U/mL), a treatment that decreased
HEt oxidation by 50% (Fig. 4). DPI (10 μM) or apocynin (300 μM),
an inhibitor of p47PHOX translocation, suppressed glucose metabolism
at 16.7 mM glucose by 70% and 62%, respectively (Fig. 5A). Addition-
ally, these inhibitors, DPI (10 μM) and apocynin (60 and 300 μM),
also impaired GSIS by 57%, 34% and 52%, respectively, at 16.7 mM
glucose; and by 56%, 44% and 52%, respectively, at 20 mM glucose
(Fig. 5B). However, no effect on insulin secretion was observed withn) of p47PHOX, p67PHOX and gp91PHOX proteins in 12 μm‐thick frozen islet sections (top
tion (yellow) of NADPH oxidase components p47PHOX, p67PHOX and gp91PHOX (green)
Fig. 5. Involvement of NADPH oxidase activity in glucose oxidation and insulin secre-
tion. A) [U–14C]‐Glucose oxidation in islets incubated in the absence or presence of
10 μM DPI and 300 μM apocynin (n=5). B) Effects of DPI and apocynin on insulin
secretion (n=5). *Pb0.05, **Pb0.01, and ***Pb0.001 vs the respective condition
without the inhibitors.
Fig. 4. Blockade of NADPH oxidase activity. The effect of PEG‐SOD (100 U/mL) or DPI
(10 μM) on superoxide levels in islets (n=3–5). **Pb0.01 and ***Pb0.001 vs control.
248 E. Rebelato et al. / Life Sciences 91 (2012) 244–249DPI (10 μM) and apocynin (60 and 300 μM) at 2.8 mM glucose (data
not shown).
Discussion
In the present study, the presence of the NADPH oxidase compo-
nents in human islets was observed at mRNA (Fig. 1) and protein
(Figs. 2 and 3) levels. Similar to that observed for rats (Oliveira
et al., 2003), a lower protein expression of NADPH oxidase compo-
nents in pancreatic islets compared to phagocytes would also be
expected for humans. In effect, this low expression of NADPH oxidase
components in human pancreatic islets was conﬁrmed by the low
protein levels of p47PHOX and p67PHOX (Fig. 2A and B). Immunohisto-
chemistry analysis showed the presence of p47PHOX, p67PHOX and
gp91PHOX (Fig. 3A) in human islets, and the expression of these
proteins in insulin-containing cells (Fig. 3B). These observations, to-
gether with those from a recent study showing the expression of
gp91PHOX, p47PHOX and the phosphorylated form of p47PHOX in normal
and diabetic human islets (Syed et al., 2011), provide further evidence
of the presence of a functional NOX2 isoform, whose activity is driven
by p47PHOX phosphorylation that leads to the translocation of the
p47PHOX/p67PHOX complex to the plasma membrane (Bedard and
Krause, 2007). In islets from rodents, p47PHOX phosphorylation is a
PKC-dependent process (Oliveira et al., 2003). The anchoring of phos-
phorylated p47PHOX to the C-terminal cytoplasmic tail of p22PHOX
would then allow the subsequent activation of NOX2 through a direct
protein–protein interaction with p67PHOX (Bedard and Krause, 2007).
NADPH oxidase was previously reported to have a role in rat pan-
creatic β-cell function. Impairment of glucose metabolism, intracellu-
lar calcium oscillations and GSIS were observed as a consequence of
the inhibition of this enzymatic activity (Imoto et al., 2008; Morgan
et al., 2009). To evaluate the effects of the inhibition of the enzyme
in human beta cells, a pharmacological inhibitor was used (Fig. 4).
Considering the non-selectivity of DPI for NOX, another NOX inhibi-
tor, apocynin, was also used. The blockade of enzyme activity by DPI
or of the p47PHOX translocation to the plasma membrane by apocynin
reduced glucose oxidation (Fig. 5A), concomitantly with the suppres-
sion of GSIS (Fig. 5B). Thus, by different approaches we observed sim-
ilar ﬁnal effects, suggesting that the activity of this enzyme is involved
in GSIS. Nonetheless, the molecular mechanism by which NADPH ox-
idase activity contributes to islet function is not yet known. However,
considering the importance of the redox control for GSIS (Rebelato et
al., 2011; Martens et al., 2005) and that even the intracellular level of
H2O2 acts as negative regulator of glucose metabolism (Rebelato et al.,
2011), this effect of NADPH oxidase inhibition on β-cell function
could occur via local action in the plasma membrane, as NOX activity
has also been implicated in the control of intracellular pH and trans-
membrane ion ﬂuxes (Bedard and Krause, 2007), or a redox microen-
vironment in the vicinity of the membrane.
Despite the rising interest in the implications of NADPH oxidase in
non-phagocytic cells, the reports were mainly carried out in rodents.
The present description of the main components of NADPH oxidase inhuman islets draws attention to further investigations on its implica-
tion also on the mechanisms underlying human β-cell dysfunction.
Conclusion
The present study demonstrated the presence of the main intrinsic
components of NADPH oxidase comprising the NOX2 isoform in human
pancreatic islets. It was also shown here that the activity of NADPH oxi-
dase is signiﬁcant for glucose metabolism and glucose-stimulated insulin
secretion in human β-cells.
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